Valneva SE
Company Profile
Business description
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
Contact
6 Rue Alain Bombard
Saint-Herblain44800
FRAT: +33 228073710
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
713
Stocks News & Analysis
stocks
Most popular shares in SMSFs
stocks
Will China strong arm BHP into lower iron ore prices?
stocks
Chart of the Week: Where Morningstar sees attractive dividend yields in 26/27
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,264.30 | 8.50 | 0.09% |
| CAC 40 | 7,918.00 | 123.36 | -1.53% |
| DAX 40 | 24,241.46 | 369.79 | -1.50% |
| Dow JONES (US) | 45,479.60 | 878.82 | -1.90% |
| FTSE 100 | 9,427.47 | 81.93 | -0.86% |
| HKSE | 26,290.32 | 462.27 | -1.73% |
| NASDAQ | 22,204.43 | 820.20 | -3.56% |
| Nikkei 225 | 48,088.80 | 491.64 | -1.01% |
| NZX 50 Index | 13,467.26 | 103.60 | -0.76% |
| S&P 500 | 6,552.51 | 182.60 | -2.71% |
| S&P/ASX 200 | 8,958.30 | 9.20 | 0.10% |
| SSE Composite Index | 3,897.03 | 36.94 | -0.94% |